Uekusa Shusuke, Mogi Keika, Ota Yuki, Hanai Yuki, Kitagawa Kohei, Yoshio Takashi, Matsuo Kazuhiro
Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University, Miyama 2-2-1, Funabashi, Chiba, 274-8510, Japan.
Department of Neuropsychiatry, Okayama Psychiatric Medical Center, Shikatahonmachi 3-16, Kita-ku, Okayama, 700-0915, Japan.
Drugs Real World Outcomes. 2024 Dec;11(4):691-700. doi: 10.1007/s40801-024-00465-8. Epub 2024 Nov 13.
Psychotropic drugs have been reported to cause urinary retention (UR) via anticholinergic and other mechanisms. However, UR has not received much attention because of its non-fatal symptoms. We investigated the occurrence of UR associated with psychotropic drugs using the Japanese Adverse Drug Event Report (JADER) database.
Using the JADER database, we calculated reporting odds ratios for UR for 74 psychotropic drugs. Multivariate logistic regression analysis was used to adjust for the effects of sex, underlying disease, and age on UR. Variable selection included forced entry for sex, age, benign prostatic hyperplasia (BPH), depression, and backward-forward stepwise selection for each drug.
A total of 887,704 cases were reported, of which 4653 (0.52%) had UR. In terms of sex, 0.79% (3401/429,372 cases) and 0.43% (1797/415,358 cases) of male and female patients had UR. In terms of age, 0.31% (892/288,676 cases) and 0.68% (3463/506,907 cases) of patients aged < 60 years and 60 years or older had UR. Among the underlying diseases, 8.22% (930/11,316 cases) and 0.43% (3723/876,388 cases) of patients with BPH and without BPH had UR, respectively. Further, 1.99% (337/16,959 cases) and 0.50% (4316/870,745 cases) of patients with depression and without depression had UR, respectively. Overall, 38 psychotropic drugs met the criteria for signal detection. In logistic regression, a total of 783,083 patients of discernible age and sex were included. The selected variables were sex, age, BPH, depression, and 23 drugs, including quetiapine [adjusted reporting odds ratio (ROR) 95% confidence interval (CI): 1.46-2.81], chlorpromazine (adjusted ROR 95%CI: 1.29-3.13), etizolam (adjusted ROR 95%CI: 1.47-3.09), maprotiline (adjusted ROR 95%CI: 1.99-8.34), mirtazapine (adjusted ROR 95%CI: 1.37-2.88), and duloxetine (adjusted ROR 95%CI: 2.15-4.21).
Many psychotropic drugs induce UR, which may be owing to their pharmacological effects. Appropriate monitoring is needed, especially in patients with other risk factors for UR.
据报道,精神药物可通过抗胆碱能及其他机制导致尿潴留(UR)。然而,由于其症状不致命,尿潴留并未受到太多关注。我们使用日本药品不良反应报告(JADER)数据库调查了与精神药物相关的尿潴留的发生情况。
利用JADER数据库,我们计算了74种精神药物的尿潴留报告比值比。采用多因素逻辑回归分析来调整性别、基础疾病和年龄对尿潴留的影响。变量选择包括性别、年龄、良性前列腺增生(BPH)、抑郁症的强制纳入,以及每种药物的前后向逐步选择。
共报告了887,704例病例,其中4653例(0.52%)发生了尿潴留。在性别方面,男性和女性患者的尿潴留发生率分别为0.79%(3401/429,372例)和0.43%(1797/415,358例)。在年龄方面,年龄<60岁和≥60岁的患者尿潴留发生率分别为0.31%(892/288,676例)和0.68%(3463/506,907例)。在基础疾病中,患有BPH和未患有BPH的患者尿潴留发生率分别为8.22%(930/11,316例)和0.43%(3723/876,388例)。此外,患有抑郁症和未患有抑郁症的患者尿潴留发生率分别为1.99%(337/16,959例)和0.50%(4316/870,745例)。总体而言,38种精神药物符合信号检测标准。在逻辑回归中,共纳入了783,083例年龄和性别可辨别的患者。所选变量为性别、年龄、BPH、抑郁症以及23种药物,包括喹硫平[调整后的报告比值比(ROR)95%置信区间(CI):1.46 - 2.81]、氯丙嗪(调整后的ROR 95%CI:1.29 - 3.13)、艾司唑仑(调整后的ROR 95%CI:1.47 - 3.09)、马普替林(调整后的ROR 95%CI:1.99 - 8.34)、米氮平(调整后的ROR 95%CI:1.37 - 2.88)和度洛西汀(调整后的ROR 95%CI:2.15 - 4.21)。
许多精神药物可诱发尿潴留,这可能归因于其药理作用。需要进行适当监测,尤其是对于有其他尿潴留危险因素的患者。